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Background: Type 2 diabetes mellitus (T2DM) is the
most common form of diabetes. Risk factors for its
development include older age, obesity, family history of
diabetes, history of gestational diabetes, impaired glu-
cose metabolism, physical inactivity, and race/ethnicity.
Objective: The purpose of this study was to
characterize T2DM burden, from a patient perspec-
tive, with respect to age and race/ethnicity.
Methods: Adults agedZ18 years with T2DM from
a large, Internet-based, nationwide survey were retro-
spectively analyzed. Demographic and clinical charac-
teristics (glycemic control, body mass index [BMI],
comorbidities, and diabetes-related complications),
hypoglycemic episodes, and medication adherence
were used to assess diabetes burden. Degree of burden
was compared across age (18–64, 65–74, and Z75
years) and racial/ethnic (white, African American,
Hispanic, Asian, and American Indian) groups.
Results: An apparent association was found be-
tween glycemic control and medication adherence.
Hispanics had the lowest percentage of participants
with a hemoglobin A1c (HbA1c) levelo7.0% (24.4%)
and the highest percentage of those not knowing their
HbA1c levels (55.4%) but also had the poorest
medication adherence among racial/ethnic groups.
Conversely, American Indians and whites had the bestAccepted for publication December 30, 2013.
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Open access under CC BY-NC-ND license.glycemic control, HbA1c knowledge, and medication
adherence. The 18- to 64-year age group had the
poorest glycemic control (28.8%), the most with
unknown HbA1c levels (46.3%), and the poorest
medication adherence of the age groups. Mean BMIs
were high (430 mg/kg2) for all racial/ethnic groups
other than the Asian group (28.9 mg/kg2). Approx-
imately 71% of Asians were obese or overweight
compared with Z90% in the other racial/ethnic
groups. Mean BMIs decreased with increasing age
group (34.5, 32.6, and 29.8 kg/m2 for the age groups
of 18–64, 65–74, and Z75 years, respectively).
Regarding diabetes-related comorbidities, the Asian
group had the lowest percentages of those with
hypertension (39.1%) and hypercholesterolemia
(46.6%). The Asian group had the lowest mean
Charlson Comorbidity Index (CCI) score (score of
1.4); the American Indian group had the highest
CCI score (score of 1.8). Of the age groups, the
65- to 74-year group had the highest percentages of
those with hypertension (69.0%) and hypercholester-
olemia (67.4%). The mean CCI scores in the 65- to
74-year and Z75-year age groups (scores of 1.8 for
both) were signiﬁcantly higher than in the 18- to 64-
year age group. The Asian group had the lowest
percentage of participants reporting hypoglycemia
(37.3%). The 18- to 64-year age group had theScan the QR Code with your phone to obtain
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J.M.S. Lopez et al.highest percentage of participants reporting hypogly-
cemia (52.7%). Limitations of this study include
selection bias (Internet-based survey), recall bias,
missing values, and descriptive analyses without ad-
justment for multiplicity.
Conclusion: There are many factors that contribute
to diabetes burden and the complexity of diabetes
management. The results of this study provide insight
from a patient perspective regarding how these factors
vary across age and race/ethnicity to aid in the
individualization of diabetes treatment. (Clin Ther.
2014;36:494–506) & 2014 The Authors. Published by
Elsevier HS Journals, Inc.
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Diabetes is an insidious public health problem. The
prevalence of diabetes in the United States has nearly
tripled in the past couple of decades. From 1990 to
2010, the prevalence of diabetes in those aged Z18
years increased from 6.6 million in 1990 to 20.7 million
in 2010.1 Type 2 diabetes mellitus (T2DM), also known
as non–insulin-dependent diabetes mellitus or adult-
onset diabetes, is the most common form of diabetes,
affecting approximately 90% to 95% of all patients
diagnosed as having diabetes. Risk factors for its
development include older age, obesity, family history
of diabetes, history of gestational diabetes, impaired
glucose metabolism, physical inactivity, and race/eth-
nicity.2–4 Age is a signiﬁcant driver of the diabetes
epidemic, with425% of the US population aged Z65
years having diabetes. The prevalence of diabetes is
expected to double in the next 20 years, in part because
of the aging of the population.5 Certain races/ethnicities
have a particularly high risk of developing T2DM. The
age-adjusted prevalence rates of T2DM in adults aged
Z20 years in 2010 were 16.1%, 12.6%, 11.8%, and
8.4% among American Indian and Alaska Natives,
African Americans, Hispanics, and Asian Americans,
respectively.6 Being overweight or obese is considered
the principal modiﬁable risk factor.4 In 2010, 84.7% of
adults aged Z18 years with diagnosed diabetes were
overweight or obese.7 There are disproportionate
increases in the prevalence rates of T2DM among
African Americans and Hispanics in overweight adults
aged 20 to 74 years; however, the differences becomeApril 2014minimal in obese and severely obese adults with
T2DM.8
Although there is evidence that factors such as age,
race/ethnicity, and obesity inﬂuence the risk of devel-
oping T2DM, fewer studies have examined how these
factors inﬂuence the burden (eg, glycemic control,
comorbidities, diabetes-related complications, risk of
mortality, medication adherence, and hypoglycemia)
in those who have T2DM. There is some evidence that
age and race/ethnicity affect the development of
diabetes-related complications and mortality. The
prevalence rates of cardiovascular disease (heart dis-
ease or stroke), hospitalization for cardiovascular
disease, end-stage renal disease (ESRD), and hospital-
ization for lower-extremity amputation have been
found to increase with increasing age.9 Rates of
diabetic complications are higher in racial/ethnic
minority populations in the United States. Compared
with non-Hispanic whites, African Americans have
higher prevalence rates of visual impairment, ESRD,
hospital discharges, and mortality; Hispanics have
higher rates of ESRD and mortality; and American
Indians have a higher mortality rate.10 A contributing
factor may be the development of diabetes at younger
ages in minorities, increasing the risk of developing
complications at a younger age. Obesity complicates
T2DM management by increasing insulin resistance
and blood glucose concentrations. Being overweight
or obese is an independent risk factor for coronary
heart disease and cardiovascular disease in patients
with T2DM. Intentional weight loss has been
associated with improved insulin action, decreased
fasting blood glucose concentrations, and reduced
need for diabetes medication. Weight loss has also
been found to decrease cardiovascular risk by
decreasing blood pressure, improving serum lipid
concentrations, and reducing serum markers of
inﬂammation.11,12
The complexity of diabetes and diabetes manage-
ment has caused an evolution in diabetes management
guidelines. Recognizing this complexity, medical treat-
ment guidelines have been broad, focusing on not only
evidence-based glycemic control targets but also the
management of comorbidities. The American Diabetes
Association (ADA) continues to recommend a general
hemoglobin A1c (HbA1c) goal of o7.0% and the
potential for additional beneﬁts with more intensive
control in selected patients, but they have recently
emphasized the individualization of treatment based495
Clinical Therapeuticson factors such as the duration of diabetes, comorbid
conditions, known cardiovascular disease or advanced
microvascular complications, hypoglycemia unaware-
ness, and other individual patient considerations.13
However, the ADA guidelines have minimal consi-
deration for management in elderly patients and even
less consideration for race/ethnicity. The compoun-
ding of health conditions in older patients results in
higher medical complexity. Recognizing this, several
diabetes organizations have recently released manage-
ment guidelines that focus on the elderly population,
such as the ADA and American Geriatric Society
consensus report on diabetes in older adults, the
South Asian consensus guidelines for the manage-
ment of hyperglycemia in geriatric patients with
diabetes mellitus, and the International Association
of Gerontology and Geriatrics, European Diabetes
Working Party for Older People, and International
Task Force of Experts in Diabetes position statement
on diabetes in older people.5,14,15 All the guidelines
agree that glycemic goals should be tailored individ-
ually for older patients based on their age, comorbid
conditions, hypoglycemia risk, and projected life ex-
pectancy, with additional considerations regarding
frailty and cognitive decline. However, these recom-
mendations are based on general treatment guidelines
that have been extrapolated to elderly populations
based on the aforementioned considerations. A con-
sensus report that was jointly authored by the ADA
and the American Geriatrics Society acknowledged the
lack of data regarding the health effects of glycemic
control in patients aged Z75 years and recommended
more research to determine race/ethnic disparities
among older adults.5
Medication adherence is an important modiﬁable
factor when considering the medical complexity of
diabetes, particularly in elderly patients. Medication
adherence has been found to predict long-term glyce-
mic control.16 However, as the population gets older,
increases in comorbidities will result in an increase
in polypharmacy. Polypharmacy has been found to
decrease adherence over time in elderly patients.17
Medication adherence may also vary across racial/
ethnic groups. Multiple studies have found that
African Americans and Hispanics have lower oral
antidiabetic medication adherence rates compared
with whites.18–25 However, the association with
race/ethnicity is not fully understood because a sys-
tematic review concluded that little is known about496the association between ethnicity and medication
adherence due to insufﬁcient evidence.26
The effect of factors such as treatment adherence
and weight on T2DM burden across age and racial/
ethnic groups is not fully understood. The purpose of
this study was to characterize T2DM patients and
understand how T2DM burden may differ across age
and race/ethnicity groups with respect to comorbid-
ities, diabetes-related complications, body mass index
(BMI), and medication adherence.
PATIENTS AND METHODS
Survey Design
Data for this descriptive analysis were taken from
the 2012 US National Health and Wellness Survey
(NHWS). The NHWS is a cross-sectional, self-admin-
istered, web-based survey administered to a sample of
adults (aged Z18 years) identiﬁed through a web-
based consumer panel.
The survey encompasses 100 various conditions.
The diabetes condition series consisted of 41 ques-
tions. The weight loss condition series consisted of 24
questions. Survey data for this analysis were collected
during the ﬁrst 3 quarters of 2012. Data from the
Current Population Survey of the US Census were
used to identify the relative proportions of age, sex,
and racial/ethnic groups in the United States. The
results of the analysis were stratiﬁed, then weighted
and projected using known population incidences for
key groups to reﬂect the demographic composition of
the US Census population.
Participant Selection
Participants were recruited through opt-in e-mails,
coregistration with other panels, e-newsletter cam-
paigns, and online banner placements. The total
sample size of the NHWS consisted of 71,157 adults.
Participants were included in this analysis if they were
adults aged Z18 years who reported a diagnosis of
T2DM, both treated and untreated.
Participant Characterization
Respondents were categorized into 1 of 3 age
groups (18–64, 65–74, and Z75 years) and 1 of 5
race/ethnicity groups (white, African American, His-
panic, Asian American, and American Indian). The
degree of blood glucose control, distribution across
weight categories, prevalence of selected comorbidities
and diabetes-related complications, hypoglycemicVolume 36 Number 4
Table I. Demographic characteristics of the
survey participants (aged Z18 years)
with T2DM.
Characteristic
No. (%) of participants*
(N ¼ 7239)
Age mean (SD), y 59.9 (12.2)
Sex
Male 4306 (59.5)
Female 2933 (40.5)
Race/ethnicity
White 5517 (76.2)
African American 828 (11.4)
Hispanic 500 (6.9)
Asian 161 (2.2)
American Indian 114 (1.6)
T2DM ¼ type 2 diabetes mellitus.
*Data are presented as number (percentage) of survey
participants unless otherwise indicated.
J.M.S. Lopez et al.episodes, mortality risk, and medication adherence
were determined for each demographic category.
Participants were considered in glycemic control if
their self-reported HbA1c levels were o7.0%. Partic-
ipants were categorized according to BMI as obese
(Z30 kg/m2), overweight (25 to o30 kg/m2), normal
weight (Z19 to o25 kg/m2), or underweight (o19
kg/m2). Comorbidities were self-reported. For all
respondents, the comorbidities of special interest were
hypertension, hypercholesterolemia, and moderate-
severe kidney disease. Diabetes-related complications
were also self-reported and included macular edema
or retinopathy, kidney disease, foot or leg ulcer,
neuropathic pain, and diabetes-related end-organ
damage. Hypoglycemic episodes were grouped as
those that were experienced any time in the past (ever
hypoglycemia) or in the previous 3 months (recent
hypoglycemia).
Mortality Risk
Mortality risk based on comorbid conditions was
calculated using the Charlson Comorbidity Index
(CCI) as another indicator of disease burden. Increas-
ing CCI score has been reported to correlate with
increased risk of mortality in T2DM patients.27,28
Adherence Characterization
Adherence to antidiabetic medications was deter-
mined using the Morisky Medication Adherence Scale
(MMAS). The MMAS is a structured, self-reported
measure, with higher scores representing higher medi-
cation adherence. The 8-item MMAS (MMAS-8) has
been validated in hypertensive patients taking antihy-
pertensive medications.29 The Malaysian version of the
MMAS-8 has been validated in patients with T2DM.30
Studies have found that higher scores in the 4-item
MMAS (MMAS-4) and the MMAS-8 are signiﬁcantly
associated with lower HbA1c levels.
16,30,31 In this
analysis, the 8-item questionnaire was truncated to 7
items, eliminating the question, “Do you sometimes
forget to take your pills?” The question was removed
to prevent confusion for those participants taking
insulin and other injectable medications to preserve
their inclusion in the study. From a reliability assess-
ment, the developer of the scale assessed the internal
consistency of the 7-item scale, and it did not signiﬁ-
cantly differ for reliability; removal of the question
decreases the internal consistency (Cronbach α) of the
MMAS from 0.680 to 0.78.29,32 A MMAS score of 7 isApril 2014categorized as high adherence, 5 to 6 is medium
adherence, and o5 is low adherence.
Statistical Analysis
Statistical analyses were conducted with IBM SPSS
Data Collection Quantum software, version 5.8.1
(SPSS Inc, Chicago, Illinois). Group comparisons were
performed using t tests or ANOVA for continuous
variables and χ2 analysis for categorical variables.
RESULTS
A total of 7239 survey participants aged Z18 years
reported a diagnosis of T2DM (Table I). The mean
age was 59.9 years, and approximately 59.5% were
male. Most were white (76.2%), followed by African
American (11.4%), Hispanic (6.9%), Asian (2.2%),
and American Indian (1.6%).
Almost a quarter (23.0%) of participants
self-reported poor glycemic control, and 41.7% did
not know their HbA1c levels (Table II). Most
participants (90.4%) were overweight or obese, with
an overall mean BMI of 33.5 kg/m2. Approximately
60% of participants reported having had high
cholesterol levels or hypertension. The mean CCI
score was 1.7.497
Table II. Clinical characteristics of the survey participants with T2DM.
Characteristic No. (%) of Participants* (N ¼ 7239)
HbA1c
o7.0% 2561 (35.4)
Z7.0% 1663 (23.0)
Unknown 3015 (41.7)
BMI (kg/m2)
Obese (Z30) 4452 (63.0)
Overweight (25 to o30) 1937 (27.4)
Normal weight (Z19 to o25) 655 (9.3)
Underweight (o19) 22 (0.3)
Mean (SD) 33.5 (7.7)
Comorbidities
Ever experienced high cholesterol levels 4450 (61.5)
Ever experienced hypertension 4515 (62.4)
Ever experienced moderate-severe kidney disease 144 (2.0)
Diabetes-related complications
Macular edema or diabetic retinopathy 323 (4.5)
Kidney disease 320 (4.4)
Foot or leg ulcer 274 (4.8)
Neuropathic pain 1463 (20.2)
None 5374 (74.2)
Charlson Comorbidity Index score
1 4747 (65.6)
2 1238 (17.1)
3 730 (10.1)
Z4 524 (7.2)
Mean (SD) 1.7 (1.3)
Antihyperglycemic agents
Oral 4109 (56.8)
Insulin only 547 (7.6)
Insulin and oral 1075 (14.9)
Other injectables (GLP-1 agonists) 313 (4.3)
Untreated 1174 (16.2)
Hypoglycemia episodes
Ever 3651 (50.4)
Recent 1898 (26.2)
Medication adherence (MMAS score)
No. 6244
High (score, 7) 2932 (47.0)
Medium (score, 5–6) 2464 (39.5)
Low (score, o5) 848 (13.6)
BMI ¼ body mass index; GLP-1 ¼ glucagon-like peptide 1; HbA1c ¼ hemoglobin A1c; MMAS ¼ Morisky Medication
Adherence Scale; T2DM ¼ type 2 diabetes mellitus.
*Data are presented as number (percentage) of survey participants unless otherwise indicated.
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diabetes burden by racial/ethnic group and age group,
respectively. There were more males with T2DM in
the white, Hispanic, and Asian groups (62.5%,
54.6%, and 66.5%, respectively) but more females
in the African American group (57.0%). The propor-
tion of men and women in the American Indian group
was about the same. The white group had the highest
mean age (61.9 years), and the Asian group had the
lowest mean age (49.3 years).
Glycemic Control
The African American and Hispanic groups had the
lowest percentages of participants with HbA1co7.0%
(26.1% and 24.4%, respectively). The percentages
were signiﬁcantly lower than the white (38.0%) and
American Indian (43.0%) groups (P o 0.001 vs both)
but not the Asian group (30.4%; P 4 0.12 vs both).
The percentage reporting glycemic control (HbA1c
o7%) for the American Indian group was signiﬁcantly
higher than the African American, Hispanic, and Asian
groups (Po 0.04 for all) but not the white group (P =
0.276). In addition to having the lowest percentages of
participants with blood glucose control, the African
American and Hispanic groups also had the highest
percentage of participants who did not know their
HbA1c levels (53.0% and 55.4%, respectively; P o
0.05 for both groups vs the white, Asian, and Amer-
ican Indian groups).
Signiﬁcantly fewer participants in the 18- to
64-year age group had HbA1c levels o7.0%
compared with the 65- to 74-year and Z75-year
age groups (28.8%, 44.4%, and 43.5%, respectively;
P o 0.001 for both). In addition, the 18- to 64-year
age group had a signiﬁcantly higher percentage of
participants who did not know their HbA1c levels
(46.3%, 34.9%, and 37.6%, respectively; P o 0.001
for both).
BMI
Mean BMIs were in the obese range (Z30 mg/kg2) for
all racial/ethnic groups (33.4, 33.8, 34.0, and 35.7 kg/
m2 for the white, African American, Hispanic, and
American Indian groups, respectively) except for the
Asian group (28.9 kg/m2), which had signiﬁcantly
lower BMIs than all other groups (P o 0.001 for all
comparisons). The percentage of Asians who were
obese or overweight was 71.3%, compared with
90.9%, 91.1%, 89.9%, and 92.8% of whites, AfricanApril 2014Americans, Hispanics, and American Indians, respec-
tively (P o 0.05 for all). At least two-thirds of
participants in the latter racial/ethnic groups were
obese, whereas the Asian group had more even
distribution among obese, overweight, and normal
weight participants.
Mean BMIs were inversely related to age; the mean
BMI in the 18- to 64-year age group (34.5 kg/m2) was
signiﬁcantly higher than in the 65- to 74-year age
group (32.6 kg/m2), which was signiﬁcantly higher
than in the Z75-year age group (29.8 kg/m2; P o
0.001 for all comparisons). The differences in mean
BMI across age groups were mainly driven by the
large percentage of participants who were obese (BMI
Z30 kg/m2) in the 18- to 64-year age group (67.7%),
which decreased with increasing age (60.4% and
41.2% in the 65- to 74-year and Z75-year age
groups, respectively).
Diabetes-Related Comorbidities, Complications,
and Disease Burden
More than half of all racial/ethnic groups experi-
enced hypertension or high cholesterol levels, with the
exception of the Asian group. The percentages of
whites, African Americans, Hispanics, and American
Indians who experienced hypertension were 64.0%,
63.8%, 50.4%, and 59.7%, respectively. The percent-
age of Asians was signiﬁcantly lower than all other
groups (39.1%; P o 0.001 for all comparisons). The
percentages of whites, African Americans, Hispanics,
and American Indians who experienced high choles-
terol levels were 64.1%, 52.2%, 53.4%, and 59.7%,
respectively. The percentage of Asians was lower than
all other groups (46.6%; P o 0.05 vs white and
American Indians). The rates of moderate-to-severe
kidney disease were similar across racial/ethnic
groups. For diabetes-related complications, the pro-
portions were similar except for the signiﬁcantly lower
rate of neuropathic pain in the Asian group (5.6%)
compared with the other racial/ethnic groups (21.6%,
15.2%, 17.0%, and 24.6% for the white, African
American, Hispanic, and American Indian groups,
respectively; P o 0.001 for all comparisons). The
Asian group had the lowest mean CCI score (score of
1.4) compared with the other racial/ethnic groups
(scores of 1.7, 1.6, 1.5, and 1.8 for the white, African
American, Hispanic, and American Indian groups,
respectively; P o 0.005 vs the White and American
Indian groups).499
Table III. Clinical characteristics and diabetes burden by age group.
Characteristic
No. (%) of Survey Participants by age*
18–64 years
(n ¼ 4151)
65–74 years
(n ¼ 2506)
Z75 years
(n ¼ 582)
Sex
Male 2446 (58.9) 1499 (59.8) 361 (62.0)
Female 1705 (41.1) 1007 (40.2) 221 (38.0)
HbA1c
o7.0% 1195 (28.8) 1113 (44.4)† 253 (43.5)†
Z7.0% 1034 (24.9)§‡ 519 (20.7) 110 (18.9)
Unknown 1922 (46.3)§‡ 874 (34.9) 219 (37.6)
BMI (kg/m2)
No. 4038 2452 576
Obese (Z30) 2735 (67.7)§‡ 1480 (60.4)‡ 237 (41.2)
Overweight (25 to o30) 986 (24.4) 717 (29.2)† 234 (40.6)†§
Normal weight (Z19 to o25) 301 (7.5) 250 (10.2)† 104 (18.1)†§
Underweight (o19) 16 (0.4) 5 (0.2) 1 (0.2)
Mean (SD) 34.5 (8.3)§‡ 32.6 (6.8)‡ 29.8 (5.7)
Comorbidities
Hypertension 2414 (58.2) 1729 (69.0)†‡ 372 (63.9)†
High cholesterol level 2395 (57.7) 1688 (67.4)†‡ 367 (63.1)†
Moderate-severe kidney disease 61 (1.5) 63 (2.5)† 20 (3.4)†
Diabetes-related complications
Macular edema or retinopathy 178 (4.3) 108 (4.3) 37 (6.4)†§
Kidney disease 153 (3.7) 132 (5.3)† 35 (6.0)†
Foot or leg ulcer 179 (4.3)§ 75 (3.0) 20 (3.4)
Neuropathic pain 825 (19.9) 514 (20.5) 124 (21.3)
End-organ damage 47 (1.1) 28 (1.1) 4 (0.7)
None 3096 (74.6)‡ 1870 (74.6)‡ 408 (70.1)
Charlson Comorbidity Index score
1 2904 (70.0)§‡ 1505 (60.1) 338 (58.1)
2 627 (15.1) 501 (20.0)† 110 (18.9)†
3 372 (9.0) 271 (10.8)† 87 (15.0)†§
Z4 248 (6.0) 229 (9.1)† 47 (8.1)†
Mean (SD) 1.6 (1.3) 1.8 (1.3)† 1.8 (1.2)†
Hypoglycemic episodes
Ever 2188 (52.7)§‡ 1206 (48.1) 257 (44.2)
Recent 1182 (28.5)§‡ 594 (23.7) 122 (21.0)
Medication adherence (MMAS score)
No. 3536 2221 487
High (score, 7) 1374 (38.9) 1259 (56.7)† 299 (61.4)†
Medium (score, 5–6) 1488 (42.1)§‡ 807 (36.3) 169 (34.7)
Low (score, o5) 674 (19.1)§‡ 155 (7.0)‡ 19 (3.9)
BMI ¼ body mass index; HbA1c ¼ hemoglobin A1c; MMAS ¼ Morisky Medication Adherence Scale.
*Data are presented as number (percentage) of survey participants unless otherwise indicated.
†P o 0.05 vs the 18- to 64-year age group.
§P o 0.05 vs the 65- to 74-year age group.
‡P o 0.05 vs the Z75-year age group.
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Table IV. Clinical characteristics and diabetes burden by race/ethnicity.
Characteristic
No. (%) of Survey Participants*
White
(n ¼ 5517)
African American
(n ¼ 828)
Hispanic
(n ¼ 500)
Asian
(n ¼ 161)
American Indian
(n ¼ 114)
Sex
Male 3446 (62.5)‡§¶ 356 (43.0) 273 (54.6)‡ 107 (66.5)‡§¶ 58 (50.9)
Female 2071 (37.5) 472 (57.0)†§|| 227 (45.4)†|| 54 (33.5) 56 (49.1)†||
Age, y
418 5517 (100.0) 828 (100.0) 500 (100.0) 161 (100.0) 114 (100.0)
18–64 2783 (50.4) 640 (77.3)† 421 (84.2)†‡ 139 (86.3)†‡ 88 (77.2)†
65–74 2193 (39.8)‡§||¶ 166 (20.1)§|| 71 (14.2) 19 (11.8) 21 (18.42)
Z75 541 (9.8)‡§|| 22 (2.7) 8 (1.6) 3 (1.9) 5 (4.4)
Mean (SD) 61.9 (11.4)‡§||¶ 55.3 (11.8)§|| 50.7 (12.6) 49.3 (13.0) 55.8 (10.9)§||
HbA1c
o7.0% 2095 (38.0)‡§ 216 (26.1) 122 (24.4) 49 (30.4) 49 (43.0)‡§||
Z7.0% 1291 (23.4) 173 (20.9) 101 (20.2) 44 (27.3) 22 (19.3)
Unknown 2131 (38.6) 439 (53.0)†||¶ 277 (55.4)†||¶ 68 (42.2) 43 (37.7)
BMI (kg/m2)
No. 5390 808 485 160 111
Obese (Z30) 3420 (63.5)|| 512 (63.4)|| 309 (63.7)|| 58 (36.3) 78 (70.3)||
Overweight (25 to o30) 1477 (27.4) 224 (27.7) 127 (26.2) 56 (35.0)†§¶ 25 (22.5)
Normal weight
(Z19 to o25)
478 (8.9) 72 (8.9) 46 (9.5) 42 (26.3)†‡§¶ 8 (7.2)
Underweight (o19) 15 (0.3) 0 (0.0) 3 (0.6)‡ 4 (2.5)†‡§ 0 (0.0)
Mean (SD) 33.4 (7.6)|| 33.8 (8.1)|| 34.0 (8.4)|| 28.9 (6.4) 35.7 (8.4)†‡||
Comorbidities
Hypertension 3528 (64.0)§|| 528 (63.8)§|| 252 (50.4)|| 63 (39.1) 68 (59.7)||
High cholesterol 3536 (64.1)‡§|| 432 (52.2) 267 (53.4) 75 (46.6) 68 (59.7)||
Moderate-severe kidney
disease
119 (2.2)‡ 8 (1.0) 10 (2.0) 2 (1.2) 1 (0.9)
Diabetes-related complications
Macular edema or
retinopathy
265 (4.8)‡ 22 (2.7) 15 (3.0) 6 (3.7) 6 (5.3)
Kidney disease 253 (4.6)‡ 24 (2.9) 26 (5.2)‡ 7 (4.4) 6 (5.3)
Foot/leg ulcer 210 (3.8) 26 (3.1) 23 (4.6) 9 (5.6) 5 (4.4)
Neuropathic pain 1192 (21.6)‡§|| 126 (15.2)|| 85 (17.0)|| 9 (5.6) 28 (24.6)‡||
End organ damage 54 (1.0) 10 (1.2) 9 (1.8) 2 (1.2) 3 (2.6)
None 4020 (72.9) 664 (80.2)†¶ 387 (77.4)†¶ 134 (83.2)†¶ 78 (68.4)
Charlson Comorbidity Index score
1 3516 (63.7) 582 (70.3)† 374 (74.8)† 123 (76.4)† 76 (66.7)
2 988 (17.9)§ 137 (16.6) 64 (12.8) 21 (13.0) 13 (11.4)
3 583 (10.6)‡§ 69 (8.3) 36 (7.2) 12 (7.5) 12 (10.5)
Z4 430 (7.8)‡§|| 40 (4.8) 26 (5.2) 5 (3.1) 13 (11.4)‡§||
Mean (SD) 1.7 (1.3)‡§|| 1.6 (1.2) 1.5 (1.2) 1.4 (0.8) 1.8 (1.4)§||
Hypoglycemic episodes
Ever 2763 (50.1)|| 416 (50.2)|| 264 (52.8)|| 60 (37.3) 78 (68.4)†‡§||
Recent 1444 (26.2) 192 (23.1) 138 (27.6) 35 (21.7) 52 (45.6)†‡§||
(continued)
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Characteristic
No. (%) of Survey Participants*
White
(n ¼ 5517)
African American
(n ¼ 828)
Hispanic
(n ¼ 500)
Asian
(n ¼ 161)
American Indian
(n ¼ 114)
Medication adherence
No. 4766 717 427 143 93
High (score, 7) 2396 (50.3)‡§|| 276 (38.5)§ 136 (31.9) 48 (33.6) 42 (45.2)§
Medium (score, 5–6) 1853 (38.9) 291 (40.6) 180 (42.2) 63 (44.1) 36 (38.7)
Low (score, o5) 517 (10.9) 150 (20.9)† 111 (26.0)†‡||¶ 32 (22.4)† 15 (16.1)
BMI ¼ body mass index; HbA1c ¼ hemoglobin A1c; MMAS ¼ Morisky Medication Adherence Scale.
*Data are presented as number (percentage) of survey participants unless otherwise indicated.
†P o 0.05 vs the white group.
‡P o 0.05 vs the African American group.
§P o 0.05 vs the Hispanic group.
||P o 0.05 vs the Asian group.
¶P o 0.05 vs the American Indian group.
Clinical TherapeuticsSigniﬁcantly more elderly participants (Z65 years)
experienced hypertension (68.0%) or high cholesterol
levels (66.5%) compared with participants 18 to 64
years of age (58.2% and 57.7%, respectively; P o
0.02 for both comparisons). A similar pattern was
observed with moderate-to-severe kidney disease,
occurring in 2.7% of elderly participants compared
with 1.5% of participants 18 to 64 years of age (P o
0.002). There were no trends between age group and
diabetes-related complications, with the exception of
kidney disease. The incidence of kidney disease in-
creased with increasing age group (3.7%, 5.3%, and
6.0% in the age groups of 18–64, 65–74, and Z75
years, respectively), although the difference between
the 65- to 74-year and Z75-year age groups was not
signiﬁcant. The mean CCI scores in the 65- to 74-year
(score of 1.8) and Z75-year (score of 1.8) age groups
were signiﬁcantly higher than in the 18- to 64-year age
group (score of 1.6; P o 0.001 for both). The
percentage of participants with a CCI score of 1
decreased with increasing age, but the percentage of
participants with CCI scores of Z2 was signiﬁcantly
higher in the elderly age groups than in the 18- to 64-
year age group (P o 0.05 for all comparisons).Hypoglycemic Episodes
At least half of all racial/ethnic groups reported
ever having experienced hypoglycemia, with the502exception of the Asian group. The percentage of Asian
participants reporting hypoglycemia (37.3%) was
signiﬁcantly lower than all other racial/ethnic groups
(50.1%, 50.2%, 52.8%, and 68.4% for the white,
African American, Hispanic, and American Indian
groups, respectively; P o 0.003 for all comparisons).
For recent hypoglycemia, the rates were not signiﬁ-
cantly different among the white, African American,
Hispanic, and Asian groups (26.2%, 23.1%, 27.6%,
and 21.7%, respectively) with the exception of the
American Indian group, whose rate (45.6%) was
signiﬁcantly higher than all other racial/ethnic groups
(P o 0.001 vs all other groups).
Self-reported hypoglycemia decreased with increas-
ing age. Hypoglycemic episodes were reported in
52.7% of participants in the 18- to 64-year age group
compared with 47.4% in the elderly age groups (P o
0.001). Of those, 54.0% and 48.9%, respectively,
were episodes that occurred in the past 3 months (P =
0.003).Medication Adherence
The Hispanic group had the lowest percentage of
participants with high medication adherence (31.9%;
P o 0.05 vs all groups except the Asian group) and
the highest percentage of participants with low med-
ication adherence (MMAS score of o5; 26.0%; P o
0.05 vs all groups except the Asian group). The whiteVolume 36 Number 4
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high medication adherence (50.3%; P o 0.001 vs all
groups except the American Indian group) and the
lowest percentage of participants with low medication
adherence (10.9%; Po 0.001 vs all groups except the
American Indian group).
Medication adherence was poorer in the 18- to 64-
year age group compared with the elderly age groups.
In the 18- to 64-year age group, 61.1% of participants
had medium-to-low medication adherence compared
with 42.5% of participants in the elderly age groups
(P o 0.002).
DISCUSSION
This large-scale, descriptive analysis identiﬁed differ-
ences in diabetes burden from a patient perspective
across age and racial/ethnic groups in a representative
US population. Of the racial/ethnic groups, American
Indians had the best glycemic control (HbA1co7.0%)
and the lowest percentage of those not knowing their
HbA1c levels. Hispanics had the poorest glycemic
control and the highest percentage of those not
knowing their HbA1c levels. American Indians had
the highest mean BMIs and Asians had the lowest
mean BMIs among the racial/ethnic groups. Whites
had the highest incidences of hypertension and high
cholesterol levels and Asians had the lowest. American
Indians had the highest mean CCI scores and Asians
had the lowest. American Indians had the highest
percentage of participants ever reporting hypoglyce-
mia, whereas Asians had the lowest. Whites had the
best adherence, as determined by the highest percent-
age of those with high adherence scores and the lowest
percentage of those with low adherence scores. His-
panics had the poorest adherence, as determined by
the highest percentage of participants with low adher-
ence scores and the lowest percentage of participants
with high adherence scores.
Of the age groups, the 18- to 64-year group had the
poorest glycemic control and the highest percentage of
those not knowing their HbA1c levels. The 65- to 74-
year age group had the best glycemic control and the
lowest percentage of those not knowing their HbA1c
levels. Mean BMI decreased with increasing age
group. The 65- to 74-year age group had the highest
incidences of hypertension and hypercholesterolemia,
and the 18- to 64-year age group had the lowest. The
65- to 74-year and Z75-year groups had equivalent
mean CCI scores, which were higher than in the 18- toApril 201464-year group. The percentage of participants ever
reporting hypoglycemia decreased with increasing age
group. Medication adherence improved with increas-
ing age group.
On the basis of the overall results, there appeared
to be an association between glycemic control and
medication adherence observed among racial/ethnic
and age groups. Notably, Hispanics had the poorest
glycemic control and most unawareness of their
HbA1c levels, as well as the poorest medication adher-
ence. Conversely, whites and American Indians had
the best glycemic control and the least unawareness of
their HbA1c levels, as well as the best medication
adherence. Interestingly, African Americans had better
adherence than Hispanics but had similar glycemic
control and unawareness of their HbA1c levels.
Among age groups, the 18- to 64-year group had
the poorest glycemic control and most unawareness of
their HbA1c levels, as well as the lowest medication
adherence.
Another notable observation was that Asians had
the lowest overall mean BMIs, the lowest rates of
hypertension and high cholesterol levels, the lowest
mean CCI score, and the fewest reports of ever having
hypoglycemia. However, Asians had the next poorest
levels of glycemic control and medication adherence
compared with Hispanics. Asians had the lowest mean
CCI score, but this ﬁnding was not signiﬁcant for
Hispanics. Thus, potential advantages that Asians have,
such as lower BMI and comorbidities, may be offset by
poor glycemic control and medication adherence.
The association between better medication adher-
ence and improved glycemic control has been de-
scribed in the literature.33 Older age has been
associated with better medication adherence, but
little is known about the association between race/
ethnicity and medication adherence.26 The results of
this analysis suggest that there is an association
between medication adherence and glycemic control
and that there are differences in both based on
race/ethnicity and age. The results support the
need for individualization and consideration of
patient perspectives, especially race/ethnicity, in the
management of T2DM. Although current treatment
guidelines emphasize the individualization of treat-
ment, more needs to be done to reduce the high rate of
treatment failure, including a focus on race/ethnicity
through cultural differences.13 Individualization of
treatment is difﬁcult because there is little insight503
Clinical Therapeuticsregarding the relative effectiveness of interventions
among age and race/ethnicity subgroups because of a
lack of clinical trial data or database analyses.34 This
study provides an initial framework on which to base
future studies.
The ﬁrst step in the individualization of therapy may
be the identiﬁcation of factors across race/ethnicity and
age that contribute to poor medication adherence. This
is a daunting task because socioeconomic, psycholog-
ical, and cultural factors may explain differences that
are attributed to race/ethnicity.26 Effective clinical stra-
tegies to improve medication adherence may be those
that reduce forgetting, such as automated reminders,
regimen simpliﬁcation, and regimen tailoring. Additio-
nal validated strategies include electronic monitoring
and motivational interviewing. Simple questioning at
routine diabetes assessments may also be effective
when the goal is to achieve or maintain glycemic
control.16 These strategies, with cultural adaptations,
could be incorporated into the diabetes management
plan of populations that have the potential for poor
medication adherence, such as Hispanics, Asians, and
African Americans. Because younger age groups also
tend to have poorer medication adherence, early
education and implementation of these strategies with
generational- and age-focused adaptations may be
beneﬁcial.
This study is limited by its descriptive design and
the fact that it was Internet based, which may not be
fully representative of the T2DM population. There
are also inherent limitations to survey studies, such as
recall bias, missing values, and variability in the
interpretation of questions. Because of limitations in
how the data were collected, the analysis cannot
examine whether persons who self-identify as mixed
race differ in terms of burden. Because this analysis
was descriptive, there was no adjustment for multi-
plicity. Some of the race/ethnicity groups were small,
making it difﬁcult to make ﬁrm generalizations. In
addition, the data are essentially “snapshots” in time
and are thus unable to characterize longitudinal trends
in diabetes burden.
CONCLUSION
This survey analysis of T2DM patients provides
insight into speciﬁc differences in diabetes burden
across age and race/ethnicity from the patient per-
spective. In this analysis, Hispanics and younger
participants had worse medication adherence and504poorer glucose control compared with other race/
ethnicities and older participants, respectively. Thus,
there are distinctive patterns of diabetes burden across
racial/ethnic and age groups that could direct more
individualized diabetes preventive care and manage-
ment practices. There is a need for further study and
speciﬁc guideline development in these subgroups to
reﬂect these differences. For instance, although elderly
patients appear to be more aware of their health status
and adherent to their treatment, their diabetes man-
agement is complicated by more comorbidities and
complications than younger patients. In addition,
more diabetes management with adaptations for
race/ethnicity and age or generational considerations
may need to be developed and applied. Given the
renewed focus on patient engagement in care provi-
sion in the United States, understanding nuances from
the patient perspective that are more likely to affect
effective management of T2DM based on racial/
ethnicity or age differences is an opportunity for
improving patient-centric care. This information
should encourage health care practitioners to not only
tailor education to the individual but also provide
topics to better engage minority populations in their
health management.
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